SCI-publicaties

Arens R, Baars PA, Jak M, Tesselaar K, van der Valk M, van Oers MH, van Lier RA. Cutting edge: CD95 maintains effector T cell homeostasis in chronic immune activation.

J Immunol. 2005 May 15;174(10):5915-20.

Circ Res. 2005 Apr 15;96(7):714-6. Epub 2005 Mar 17.

van Beers EJ, Peters M, Biemond BJ. [Pathophysiology and treatment of sickle-cell disease]

Ned Tijdschr Geneeskd. 2005 May 21;149(21):1144-9. Review. Dutch.

Bisoendial RJ, Kastelein JJ, Levels JH, Zwaginga JJ, van den Bogaard B, Reitsma PH, Meijers JC, Hartman D, Levi M, Stroes ES. Activation of inflammation and coagulation after infusion of C-reactive protein in humans.

Circ Res. 2005 Apr 15;96(7):714-6. Epub 2005 Mar 17.

Breems DA, Boogaerts MA, Dekker AW, Van Putten WL, Sonneveld P, Huijgens PC, Van der Lelie J, Vellenga E, Gratwohl A, Verhoef GE, Verdonck LF, Lowenberg B. Autologous bone marrow transplantation as consolidation therapy in the treatment of adult patients under 60 years with acute myeloid leukaemia in first complete remission: a prospective randomized Dutch-Belgian Haemato-Oncology Co-operative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) trial.
Br J Haematol. 2005 Jan;128(1):59-65.

Breems DA, Van Putten WL, Huijgens PC, Ossenkoppele GJ, Verhoef GE, Verdonck LF, Vellenga E, De Greef GE, Jacky E, Van der Lelie J, Boogaerts MA, Lowenberg B. Prognostic index for adult patients with acute myeloid leukemia in first relapse.
J Clin Oncol. 2005 Mar 20;23(9):1969-78. Epub 2005 Jan 4.

Deloose ST, Smit LA, Pals FT, Kersten MJ, van Noesel CJ, Pals ST. High incidence of Kaposi sarcoma-associated herpesvirus infection in HIV-related solid immunoblastic plasmablastic diffuse large B-cell lymphoma.
Leukemia. 2005 May;19(5):851-5.

Dicker F, Kater AP, Fukuda T, Kipps TJ. Fas-ligand (CD178) and TRAIL synergistically induce apoptosis of CD40-activated chronic lymphocytic leukemia B cells.
Blood. 2005 Apr 15;105(8):3193-8. Epub 2004 Aug 31.

Glas AM, Kersten MJ, Delahaye LJ, Witteveen AT, Kibbelaar RE, Velds A, Wessels LF, Joosten P, Kerkhoven RM, Bernards R, van Krieken JH, Kluin PM, van´t Veer LJ, de Jong D. Gene expression profiling in follicular lymphoma to assess clinical aggressiveness and to guide the choice of treatment.
Blood. 2005 Jan 1;105(1):301-7. Epub 2004 Sep 2.

van Hulst M, Bilgin YM, van de Watering LM, de Vries R, van Oers MH, Brand A, Postma MJ. Cost-effectiveness of leucocyte-depleted erythrocyte transfusion in cardiac valve surgery.

Transfus Med. 2005 Jun;15(3):209-17. 

Hunting CB, Noort WA, Zwaginga JJ. Circulating endothelial (progenitor) cells reflect the state of the endothelium: vascular injury, repair and neovascularization.
Vox Sang. 2005 Jan;88(1):1-9. Review.

van Imhoff GW, van der Holt B, MacKenzie MA, Ossenkoppele GJ, Wijermans PW, Kramer MH, van ´t Veer MB, Schouten HC, van Marwijk Kooy M, van Oers MH, Raemaekers JM, Sonneveld P, Meulendijks LA, Kluin PM, Kluin-Nelemans HC, Verdonck LF; Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON). Short intensive sequential therapy followed by autologous stem cell transplantation in adult Burkitt, Burkitt-like and lymphoblastic lymphoma.
Leukemia. 2005 Jun;19(6):945-52.

Kater AP, Dicker F, Mangiola M, Welsh K, Houghten R, Ostresh J, Nefzi A, Reed JC, Pinilla C, Kipps TJ. Inhibitors of XIAP sensitize CD40-activated chronic lymphocytic leukemia cells to CD95-mediated apoptosis.
Blood. 2005 Sep 1;106(5):1742-8. Epub 2005 May 24.

Mackus WJ, Kater AP, Grummels A, Evers LM, Hooijbrink B, Kramer MH, Castro JE, Kipps TJ, van Lier RA, van Oers MH, Eldering E. Chronic lymphocytic leukemia cells display p53-dependent drug-induced Puma upregulation.
Leukemia. 2005 Mar;19(3):427-34.

Nolte MA, Arens R, van Os R, van Oosterwijk M, Hooibrink B, van Lier RA, van Oers MH. Immune activation modulates hematopoiesis through interactions between CD27 and CD70.
Nat Immunol. 2005 Apr;6(4):412-8. Epub 2005 Feb 20.

Piriou E, Jansen CA, Dort K, De Cuyper I, Nanlohy NM, Lange JM, van Oers MH, Miedema F, van Baarle D. Reconstitution of EBV latent but not lytic antigen-specific CD4+ and CD8+ T cells after HIV treatment with highly active antiretroviral therapy.
J Immunol. 2005 Aug 1;175(3):2010-7.

Piriou E, van Dort K, Nanlohy NM, van Oers MH, Miedema F, van Baarle D. Loss of EBNA1-specific memory CD4+ and CD8+ T cells in HIV-infected patients progressing to AIDS-related non-Hodgkin Lymphoma.
Blood. 2005 Jul 12; [Epub ahead of print]

Piriou ER, van Dort K, Nanlohy NM, van Oers MH, Miedema F, van Baarle D. Novel method for detection of virus-specific CD41+ T cells indicates a decreased EBV-specific CD4+ T cell response in untreated HIV-infected subjects.
Eur J Immunol. 2005 Mar;35(3):796-805.

Rouschop KM, Roelofs JJ, Claessen N, da Costa Martins P, Zwaginga JJ, Pals ST, Weening JJ, Florquin S. Protection against renal ischemia reperfusion injury by CD44 disruption.
J Am Soc Nephrol. 2005 Jul;16(7):2034-43. Epub 2005 May 18.

van Royen N, Schirmer SH, Atasever B, Behrens CY, Ubbink D, Buschmann EE, Voskuil M, Bot P, Hoefer I, Schlingemann RO, Biemond BJ, Tijssen JG, Bode C, Schaper W, Oskam J, Legemate DA, Piek JJ, Buschmann I. START Trial: a pilot study on STimulation of ARTeriogenesis using subcutaneous application of granulocyte-macrophage colony-stimulating factor as a new treatment for peripheral vascular disease.
Circulation. 2005 Aug 16;112(7):1040-6. Epub 2005 Aug 8.

Spijkers PP, da Costa Martins P, Westein E, Gahmberg CG, Zwaginga JJ, Lenting PJ. LDL-receptor-related protein regulates beta2-integrin-mediated leukocyte adhesion.
Blood. 2005 Jan 1;105(1):170-7. Epub 2004 Aug 24.

Ulfman LH, Alblas J, van Aalst CW, Zwaginga JJ, Koenderman L. Differences in potency of CXC chemokine ligand 8-, CC chemokine ligand 11-, and C5a-induced modulation of integrin function on human eosinophils.
J Immunol. 2005 Nov 1;175(9):6092-9.

Non SCI-publicaties

Bilgin YM, Van de Watering LMG,  Eijsman, Versteegh MIM, van Oers  MHJ, Brand A. Bloedtransfusies en postoperatieve complicaties na hartklepchirurgie.

HART BULLETIN 2005, 36(4), 108-112

Gallegos Ruiz MI, van Oers MHJ, Kersten MJ. Rituximab: de ´magic bullet´ in de bestrijding van het B-cel-non-Hodgkin-lymfoom? Werkingsmechanismen en mogelijke oorzaken van resistentie.

NED TIJDSCHR HEMATOLOGIE 2005, 2(5), 184-191

Hunting CB, Deloose STP, de Valk B, Kersten MJ. Ziekte van Castleman.

NED TIJDSCHR HEMATOLOGIE 2005, 2(1), 22-27.

Juffermans NP, Jager A, Kersten MJ, van Oers MH, Hommes DW. [Epstein-Barr virus-related lymphomas in patients with inflammatory bowel disease]
Ned Tijdschr Geneeskd. 2005 Aug 13;149(33):1859-63. Dutch.

EJHP Practice 2005, II(4), 18-19.

NED TIJDSCHR HEMATOLOGIE 2005, 2(4), 132-139.

Overige publicaties

In RM Romero (Ed.), Trends in leukemia research 2005, (pp. 363-383). s.l.: Nova Science Publishers, Inc.

In Immuuntherapie van hematologische ziekten 2005; (pp. 41-46).

In Immuuntherapie van hematologische ziekten 2005; (pp. 85-91).

Promotie

31-03-2005

(Co-)promotor:  Miedema F, van Oers MHJ, van Baarle D.